206 related articles for article (PubMed ID: 19208831)
1. Is anticancer drug development heading in the right direction?
Hambley TW; Hait WN
Cancer Res; 2009 Feb; 69(4):1259-62. PubMed ID: 19208831
[TBL] [Abstract][Full Text] [Related]
2. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
4. Perspectives on the development of a molecularly targeted agent.
Druker BJ
Cancer Cell; 2002 Feb; 1(1):31-6. PubMed ID: 12086885
[TBL] [Abstract][Full Text] [Related]
5. [STI571: a summary of targeted therapy].
Czyz M; Jakubowska J
Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
[TBL] [Abstract][Full Text] [Related]
6. STI571 (imatinib mesylate): the tale of a targeted therapy.
Thambi P; Sausville EA
Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
[TBL] [Abstract][Full Text] [Related]
7. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
Druker BJ
J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
10. STI571 (Gleevec) as a paradigm for cancer therapy.
Druker BJ
Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
[TBL] [Abstract][Full Text] [Related]
11. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
12. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
13. A hope for the future.
Silver RT
Cancer Invest; 2003 Jun; 21(3):486. PubMed ID: 12901295
[No Abstract] [Full Text] [Related]
14. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Sawyers CL
Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
[TBL] [Abstract][Full Text] [Related]
15. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
16. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
17. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814
[No Abstract] [Full Text] [Related]
18. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
19. New drug targets genetic malfunction in chronic myeloid leukemia.
Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
[No Abstract] [Full Text] [Related]
20. Transporter pumps and imatinib: a cause of pharmacokinetic resistance?
Klumpen HJ; Liddle C; Gurney H
Cancer Biol Ther; 2008 Mar; 7(3):416-8. PubMed ID: 18334863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
